- E-post
- thomas.helland@uib.no
- Besøksadresse
-
Haukeland universitetssykehus
5009 Bergen - Postadresse
-
Postboks 7804
5020 Bergen
Publikasjoner
2024
- Laughlin, Anna M. Mc; Helland, Thomas; Klima, Fenja et al. (2024). Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. (ekstern lenke)
- Kaur, Jaspreet; Jung, Sung Yun; Austdal, Marie et al. (2024). Quantitative proteomics reveals serum proteome alterations during metastatic disease progression in breast cancer patients. (ekstern lenke)
- Lee, Oukseub; Bazzi, Latifa A.; Xu, Yanfei et al. (2024). A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects. (ekstern lenke)
- Mellgren, Gunnar; Helland, Thomas; Jonsdottir, Kristin et al. (2024). Håvard Søiland. (ekstern lenke)
2023
- Khan, Seema A.; Mi, Xinlei; Xu, Yanfei et al. (2023). Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women with Ductal Carcinoma in Situ: A Randomized Clinical Trial. (ekstern lenke)
- Eliassen, Finn; Blåfjelldal, Vibeke Iren Jensen; Helland, Thomas et al. (2023). Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. (ekstern lenke)
2021
- Chen, Yuanhuang; Marcath, Lauren A.; Eliassen, Finn Magnus et al. (2021). Effect of genetic variability in 20 pharmacogenes on concentrations of tamoxifen and its metabolites. (ekstern lenke)
- Helland, Thomas; Alsomairy, Sarah; Lin, Chenchia et al. (2021). Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer. (ekstern lenke)